UHND.com - Notre Dame Football, Basketball, & Recruiting

RCT could? The good Doctor may be an excellent Family Physician, but he's not a Virologist or Epidemiologist who practices in those fields for a living. Those who are professionals in those fields like Dr. Risch's peers at Yale Medical School and the American Journal of Epidemiology have publicly gone on record denouncing HCQ+ as a treatment for COVID-19.

The fundamental reason why HCQ+ never got FDA approval is because Dr. Risch, Dr. Fareed, Dr. Tyson and other "Sponsors" of that drug treatment failed to provide data from an RCT that proved any benefit in the manner of usage they recommended. If they truly believed in it, they should have ponied up the money and conducted it...like Pfizer did with "Paxlovid"...a drug treatment that was so successful the FDA halted the trials early in order to get it out to the public asap.

Here's an AI summary to the question of whether or not proponents of HCQ+ had ever done an RCT for their recommended treatment...

--------------------
AI Overview

Submission of RCT data for FDA approval of hydroxychloroquine (HCQ) for COVID-19

While hydroxychloroquine (HCQ) was temporarily authorized for emergency use in hospitalized patients with COVID-19 based on limited evidence in 2020, the FDA later revoked this Emergency Use Authorization (EUA) in June 2020. This revocation was based on mounting evidence, including data from a large randomized controlled trial, indicating that the potential benefits did not outweigh the risks.

The FDA issued the EUA for HCQ for COVID-19 based on limited in-vitro and anecdotal clinical data available at the time. However, the EUA itself stated that the authorization was for the unapproved use of the drug in specific hospitalized patients where a clinical trial was not available or participation wasn't feasible.

The FDA recommends that the use of HCQ for COVID-19 should be limited to clinical trial settings or for treating certain hospitalized patients under the EUA (which has since been revoked). Healthcare professionals were advised to check ClinicalTrials.gov for suitable clinical trials and consider enrolling patients in such trials.

Therefore, to answer the question directly, sponsors of HCQ did not submit randomized controlled trial (RCT) data specifically for FDA approval of HCQ as a COVID-19 treatment. The EUA was based on limited data and was subsequently revoked after RCTs, like the RECOVERY trial, showed no evidence of benefit for mortality or other outcomes in hospitalized patients with COVID-19.
---------------------

Thankfully, the COVID-19 pandemic is behind us, so there's no need to keep beating this horse...but keep in mind the lesson learned when it comes to the next viral threat...which will definitely come some day...perhaps too soon with RFK Jr. at the helm of HHS...i.e. Conduct rigorous RCTs for any prospective drug that would be distributed to millions if not billions of human beings.